Skip to main content

Table 1 Pre-treatment clinical characteristics and duration of ADT in the pT0 and non-pT0 groups

From: Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer

  pT0 (N = 24) non-pT0 (N = 44) p value
Age, yr    
   Median 67 69 0.25
   Range 56-76 54-75  
PSA level, ng/ml    
   Median 10 11.3 0.261
   Range 4.8-29.0 4.9-73.9  
Clinical stage (%)    
T1c 8 (33.3) 16 (36.4) 0.865
T2a 10 (41.7) 18 (40.9)  
T2b 3 (12.5) 7 (15.9)  
T2c 3 (12.5) 3 (6.8)  
Gleason score (%)    
≤ 6 7 (29.2) 12 (27.3) 0.227
7 11 (70.8) 27 (61.4)  
≥ 8 0 (0.0) 5 (11.4)  
Risk* (%)    
Low 4 (16.7) 9 (20.5) 0.887
Intermediate 10 (41.7) 16 (36.4)  
High 10 (41.7) 19 (43.2)  
Duration of ADT, mo    
Median 9 7.5 0.022
Range 3-19 3-29  
n PSA before PRx ** (%)    
< 0.2 ng/ml 24 (100) 39 (88.6) 0.219
> 0.2 ng/ml 0 5 (11.4)  
  1. * According to D'Amico et al [18]
  2. ** nadir PSA before prostatectomy